Vol. 12 No. 1 (2022)

View Vol. 12 No. 1 (2022)

What we know and what we do not know about the impact of COVID-19 on the drug situation and response in Central-Eastern European countries?

Guest editor: Artur Malczewski

Published: 2022-05-27

Introduction

What we know and what we do not know about the impact of COVID-19 on the drug situation and response in Central-Eastern European countries? – Introduction

Artur Malczewski

1-3
- PDF

Articles

Impact of COVID-19 on drug markets, use, harms and drug services in Europe

Alessandro Pirona, João Matias, Linda Montanari, Katerina Skarupova, Marica Ferri, Isabelle Giraudon, Jane Mounteney, Sandrine Sleiman, Katarzyna Natoniewska, Bruno Guarita, Liesbeth Vandam, Tim Surmont, Paul Griffiths

4–7
- PDF
The impact of the COVID-19 pandemic on drug demand and supply in Estonia

Katri Abel-Ollo, Margo Kivila, Aljona Kurbatova, Svetlana Ovsjannikova

8–16
- PDF
The COVID-19 impact on the illegal retail drugs market in Latvia and drug use patterns

Agnese Zīle-Veisberga

17–27
- PDF
COVID-19 and the drug situation in Lithuania

Evelina Pridotkienė, Rūta Gedminienė, Rasa Povilanskienė, Brigita Rašimaitė, Viktorija Stifanovičiūtė

28–41
- PDF
Has the COVID-19 pandemic changed substance use patterns, drug market and drug response in Poland?

Artur Malczewski, Michał Kidawa, Małgorzata Dalmata

42–58
- PDF
Impact of the COVID-19 pandemic on drug markets, prevention and treatment in Ukraine

Maria Bevz

59–64
- PDF